Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Sigurjonsdottir, J F
Sigurdsson, H H
Sigfusson, S D
MetadataShow full item record
CitationInt J Pharm. 2001, 212(1):29-40
AbstractThe cyclodextrin solubilization of three benzodiazepines, i.e. alprazolam, midazolam and triazolam, was investigated. The cyclodextrin solubilization was enhanced through ring-opening of the benzodiazepine rings and ionization of the ring-open forms. Additional enhancement was obtained through interaction of a water-soluble polymer with the cyclodextrin complexes. The ring-opening was pH-dependent and completely reversible, the ring-open forms dominating at low pH but the ring-closed forms at physiologic pH. The ring-closed forms were rapidly regenerated upon elevation of pH. In freshly collected human serum in vitro at 37 degrees C, the half-life for the first-order rate constant for the ring-closing reaction was estimated to be less than 2 min for both alprazolam and midazolam. Midazolam (17 mg/ml) was solubilized in aqueous pH 4.3 nasal formulation containing 14% (w/v) sulfobutylether beta-cyclodextrin, 0.1% (w/v) hydroxypropyl methylcellulose, preservatives and buffer salts. Six healthy volunteers received 0.06 mg/kg midazolam intranasally and 2 mg intravenously, and blood samples were collected up to 360 min after the administration. Midazolam was absorbed rapidly reaching maximum serum concentrations of 54.3+/-5.0 ng/ml at 15+/-2 min. The elimination half-life of midazolam was 2.2+/-0.3 h and the absolute availability was 73+/-7%. All mean values+/-SEM.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans.
- Authors: Gudmundsdottir H, Sigurjonsdottir JF, Masson M, Fjalldal O, Stefansson E, Loftsson T
- Issue date: 2001 Dec
- Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
- Authors: Knoester PD, Jonker DM, Van Der Hoeven RT, Vermeij TA, Edelbroek PM, Brekelmans GJ, de Haan GJ
- Issue date: 2002 May
- A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
- Authors: Wermeling DP, Record KA, Archer SM, Rudy AC
- Issue date: 2009 Feb
- Pharmacokinetics and pharmacodynamics of nasally delivered midazolam.
- Authors: Haschke M, Suter K, Hofmann S, Witschi R, Fröhlich J, Imanidis G, Drewe J, Briellmann TA, Dussy FE, Krähenbühl S, Surber C
- Issue date: 2010 Jun
- In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
- Authors: Masica AL, Mayo G, Wilkinson GR
- Issue date: 2004 Oct